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Background: Symptomatic Primary Humoral Immunodeficiency Diseases (PHID) constitute a highly heterogeneous
group of diseases characterized by a shared hypogammaglobulinemia, resulting in increased risk of recurrent or
severe infections. Associations have been described with a variety of immunological abnormalities involving B
and T-cell differentiation, T-cell activation and innate immunity. However, PHID discrimination remains based on
B-lymphocyte abnormalities and other components of the immune system have not been sufficiently taken into
account. We carried out unsupervised and supervised methods for classification in a cohort of 81 symptomatic
PHID patients to evaluate the relative importance of 23 immunological parameters and to select relevant markers
that may be useful for diagnosis and prognosis.
Results: We identified five groups of patients, among which the percentage of PHID complications varied
substantially. Combining the set of markers involved in PHID supported the existence of two distinct mechanisms
associated with complications. Switched memory B-cell attrition and CD8+ HLA-DR + activated T-cell increase were
the prominent abnormalities observed in PHID complications. Furthermore, in a subgroup of 57 patients with
common variable immunodeficiency, the classification that added CD8+ HLA-DR + to the consensual EUROclass
classification was better than the EUROclass model in predicting complications.
Conclusion: These results highlight the importance of T-cell activation that may improve discrimination of PHID
patients in specific subgroups and help to identify patients with different clinical outcomes.
Keywords: Symptomatic primary humoral immunodeficiency, T-cell activation, HLA-DR marker, Hierarchical
clustering, Principal component analysis, Common variable immunodeficiency, IgG subclass deficiency, Good’s
syndromeBackground
Primary Humoral Immunodeficiency Diseases (PHID)
are a heterogeneous group of diseases characterized by a
deficit in immunoglobulin (Ig) production, resulting in
increased risk of recurrent or severe infections [1].
In adults, after elimination of secondary causes, in* Correspondence: rodolphe.thiebaut@isped.u-bordeaux2.fr; jean-francois.
viallard@chu-bordeaux.fr
1INSERM, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, Bordeaux
F-33076, France
13Department of Internal Medicine and Infectious Diseases, Bordeaux
University Hospital, Pessac F-33604, France
Full list of author information is available at the end of the article
© 2014 Picat et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the orparticular lymphoid hemopathies, drug-related causes or
renal/digestive leakage of Ig, three major symptomatic
PHID have to be entertained: Common Variable Im-
munoDeficiency [2] (CVID), IgG SubClass ImmunoDefi-
ciency [3] (IgG SD) or Good’s syndrome [4]. Although
recurrent respiratory tract infections is common to
nearly all patients with symptomatic PHID, distinct
clinical complications have been described [5-7] accor-
ding to the occurrence of autoimmune manifestations,
lymphoid hyperplasia, chronic enteropathy, spleno-
megaly and/or granulomatous disease. It has been shown
that both outcome and prognosis vary within thesed. This is an Open Access article distributed under the terms of the Creative
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lin substitution reduces the incidence of acute infections
but does not solve the appearance of complications that
are the major cause of morbidity and death among
patients with symptomatic PHID [4,8].
The various attempts of PHID classifications have fo-
cused on CVID because of their frequency [2]. Different
classification proposals have attempted to define CVID
using flow cytometry techniques based on B-cell differen-
tial phenotyping [9,10]. Recently, data from the EURO-
class group including over 300 European CVID patients,
unified previous findings with a classification based on the
percentage of B cells among circulating lymphocytes and
the percentage of switched memory B cells (smB) among
B cells [5]. However, this updated classification does not
include other components of immune dysregulation,
either causal or consequential, that have been reported in
CVID patients. Giovanetti et al. [11] performed an in-
depth analysis of the T-cell compartment in CVID patients
and demonstrated multiple T-cell abnormalities. T-cell ac-
tivation is an important process underlined [12,13] that
need to be explored, together with T-cell regulation
[14,15]. Indeed, gammadelta T cells [16] and innate cell
abnormalities reported in Natural Killer cells (NK) [17] or
myeloid dendritic (mDC) and plasmacytoid dendritic cells
(pDC) [18] may further contribute to the heterogeneous
presentation of CVID. Literature on IgG subclass defi-
ciency is poor and immunological characteristics of these
patients have not been explored as they have been in
CVID. In parallel, Good’s syndrome is characterized by
hypogammaglobulinemia and thymoma, low or absent B
cells, variable defects in cell-mediated immunity with a
CD4 T lymphopenia, an inverted CD4/CD8+ T-cell ratio
and reduced T-cell mitogen proliferative responses [4].
Because of its intrinsic complexity, distinguishing
patients with symptomatic PHID in practice can be chal-
lenging. Particularly, the median delay of diagnosis re-
ported in CVID is 7 years [2]. Some patients with IgG
subclass deficiency might develop non infectious compli-
cations as those observed in CVID [19], suggesting that
these two entities could have common determinants.
Moreover, IgG subclass deficiency may progress to have
typical common variable immunodeficiency [3]. The
immunophenotypic evaluation of symptomatic PHID
could provide diagnostic clues as well as information use-
ful to manage patients, to predict clinical outcomes
[20,21] and to improve classification schemes. The pur-
pose of our study was therefore to characterize subgroups
of PHID patients that could be defined by differentiation,
activation and regulation markers of B and T-lymphocytes
expressing αβ or γδ TCR, natural killer cells and dendritic
cells using supervised and unsupervised methods of classi-
fication appropriate for the high-dimensional data [22]
generated by flow cytometry [23,24].Methods
Design and data collection
The ALTADIH Cohort is a prospective hospital-based
cohort of symptomatic PHID patients [1], initiated at
the Bordeaux University Hospital and five other public
hospitals (Agen, Dax, Limoges, Pau and Toulouse) in
Aquitaine, South-Western France. First patients were
enrolled in 2007. Patients included were over eighteen
years old with primary hypogammaglobulinemia (serum
IgG level < 5 g/L for CVID, or IgG subclass deficiency
or Good’s syndrome). They were already followed for
symptomatic or newly diagnosed PHID (Ig level deter-
mined before substitution therapy). Differential diagno-
ses of hypogammaglobulinemia have been excluded and
the reduction in the level of the seric gammaglobulins
was confirmed at least 3 times at 3-month intervals for
each patient, thus excluding transient hypogammaglobu-
linemia. A standardized questionnaire was filled by physi-
cians at each hospital contact, according to routine clinical
management procedures, generally every 6 months. Clin-
ical data collected focused on infections and PHID com-
plications while biological data focused on innate and
adaptive markers.
The ALTADIH Cohort was approved by the Bordeaux
University Institutional Review Board on December
20th, 2006. Each patient gave informed written consent
before participating in the study. Some PHID patients
were also enrolled in the French national prospective
Cohort DEFI [7].
In this paper, the study is cross-sectional. We only deal
with inclusion measurements.
Flow cytometric analysis of peripheral blood lymphocytes
Peripheral blood samples were collected at each visit for
systematic lymphocyte phenotyping of PHID patients
under or not current immunoglobulin substitution.
Blood samples from each contributing center were ana-
lyzed centrally at the Bordeaux University Hospital
Laboratory of Immunology, by flow cytometry using a
FC500 flow cytometer from Beckman-Coulter.
All blood samples were withdrawn on EDTA anti-
coagulant in Vacutainers 5 ml tubes (BD, Biosciences,
Mountain View, CA) and kept at room temperature
until processed. All samples were analyzed fresh follow-
ing withdrawal within a working day. Following manu-
facturer recommendations, labeling were carried out
on whole blood and red blood cells lyzed at room
temperature with a Versalyse (Beckman-Coulter, France,
ref = A0937) lysing solution added with Iotest fixative so-
lution (Beckman-Coulter, France, ref = A07800). Events
were acquired with the dedicated CXP-1 software. In
these settings, we did not use any viability staining.
Unless specified, all monoclonal antibodies were pur-
chased from Beckman-Coulter (France) whose catalog
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Table S1. We used the following panel of monoclonal
antibodies (Mab):
– B cells subsets: anti- CD19 (ref: A07766), -CD27
(ref: 6607107), -CD21 (ref: PN IMU473U) and -sIgD
(ref: 736000)
– CD8+ T-cell differentiation: anti-CD8 (ref: A07756),
-CD45RA (ref: PN IM 271U), -CCR7 from R&D
(Minneapolis, MN, USA ref: FAB197A)
– HLA-DR T-lymphocyte activation markers, we used
the following panel of Mab: anti-CD45, -3, -4 and -8
(ref: 6607013) -HLA-DR (ref: PNA40579).
– CD25 T-lymphocyte activation marker: anti-CD3, -4
and -8 (ref: 6607013) -CD25 (ref: IM2646)
– CD28 T-lymphocyte activation marker: anti-CD3, -4
and -8 (ref: 6607013) -CD28 (ref: 6607108)
– CD38 T-lymphocyte activation marker: anti-CD3, -4
and -8 (ref: 6607013) -CD38 (ref: A07780)
– regulatory T-cell: anti-CD4 (ref: A07750), -CD25
(ref: IM2646) -CD127 (ref: PN IM1980U)
– NK and B cells: anti-CD45, -56, -19 and -3
(ref: 6607073) -CD16 (ref: A07766)
– myeloid and plasmacytoid dendritic cells, we used
the Beckman Coulter kit (ref: A23413 for mDC and
A23416 for pDC).
– T cells expressing the gamma/delta TCR: anti-
Vdelta2 (ref: PN IM1464) and anti-pan-delta
(ref: PN IM1418U).
T and B-cell subpopulation counts were obtained
using the flow count beads kit from Beckman-Coulter
Flow Count (ref: 7547053) following a lyse and no wash
procedure according to the manufacturer's recommen-
dations. Markers of CD4+ T-cell differentiation were not
performed in this study.
Results are expressed as percentages of total circulating
lymphocytes or of CD19+, CD3+, CD4+ or CD8+ lym-
phocytes as appropriate, and/or absolute counts in cells/
mm3 as appropriate. An exception are dendritic cells,
whose numbers are expressed per milliliter of blood, ob-
tained by calculations from the leukocyte count.
Concerning the gating strategies, as examples, we
choose to show in Additional file 2: Figure S1, the gating
strategy used to assessed CD3+, CD3 + CD4+, CD3 +
CD8+, and the proportion of cells expressing HLA-DR
among these subsets: in Panel A, applied to a normal
healthy donor whereas, in Panel B, applied to a CVID
patient. Panel C depicts the B/NK cells phenotyping of
the CVID patient.
Statistical analyses
Analyses were performed using SAS® 9.1 (SAS Institute,
Inc., Cary, NC) and XLSTAT® 2010 software (Addinsoft,Paris, France). Clinical and therapeutic data were de-
scribed as numbers and percentages. Immunoglobulin
serotypes and immunological markers were described as
medians and InterQuartile Range values (IQR). We con-
ducted multidimensional exploratory analyses (principal
component analysis and cluster analysis) to study the
links between immunological markers and clinical char-
acteristics. To run the multidimensional exploratory ana-
lyses, CD19+ B cells, CD3+, CD4+, CD8+ T cells,
regulatory T cells, NK cells and gamma/delta T-cells have
been used in absolute counts (cells/mm3). CD3 +HLA-
DR+ activated T cells have been used in percentages of
CD3+, CD4 +HLA-DR + in percentages of CD4+, and
CD8 +HLA-DR + in percentages of CD8+. Differentiation
markers of T-cells and CD8 + CD57+ have been used in
percentages of CD8+ and differentiation markers of B-
cells have been used in percentages of CD19+. Numbers
of dendritic cells were expressed per milliliter of blood
and gamma/delta2 T-cells in percentages of gamma/delta
T-cells. The use as absolute numbers or percentage has
been defined before performing any statistical analyses
(see Tables with each immunological marker for a sum-
mary of the units used to run the multidimensional ex-
ploratory analyses). Robustness analyses have been
performed using absolute count in place of percentage
and vice versa and results were not substantially different.
Principal component analysis
Principal Component Analysis (PCA) is an unsupervised
dimension-reduction method that generates Principal
Components (PC), that are linear combinations of the
original variables [25] (in our case, represented by differ-
entiation, activation and regulation markers of B and
T-lymphocytes, natural killer cells, dendritic cells and
T-cells expressing a gamma/delta TCR). Each compo-
nent explains a part of the variability of the data. We
used 2D plots to project data on the plane spanned by
the first two components to display 23 immunological
markers involved in PHID (missing data excluded). As
data run in the principal component analysis have been
normalized as referred to the sample (minus sample
mean and divided by standard deviation), data are
presented on a unit correlation circle of radius 1
(see Figure 1). Because each component is a weighted
linear combination of the original variables, a compo-
nent may have a meaning according to the contribution
of each immunological marker. We chose to present the
plan spanned by the two major principal components
because they explained the most, variability of data
(> 10%). On this plan, the contribution of markers is un-
equal and depends on the contribution of each marker
on each axis. A given marker may contribute on the
third axis and therefore would not be well represented
on the first two axes. PCA was also performed in CVID
PC1 (27%) 
Figure 1 23 immunological markers involved in PHID, plotted on the first two Principal Components (PC). ALTADIH Cohort, 2007-2010.
Immunological markers are well represented by the component when they are far from the center and close to the corresponding axis. Two
markers are: 1) positively correlated if close to each other; 2) not correlated if in a rectangular position; 3) negatively correlated if on the
opposite side.
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given in Additional file 3: Figure S2.
Cluster analysis
Hierarchical clustering is a common method used to de-
termine clusters of similar data points [26]. Ward’s hier-
archical clustering method was used here [27]. This
method aggregates consecutively the patients presenting
the closest immunological characteristics, by maximizing
inter-class variance using Ward’s criterion. This process
leads to the construction of a classification tree (patients
with missing immunological data excluded), which
allowed us to identify some distinct subgroups of PHID
patients. The projection of the identified clusters onto
the first two principal components then helped us
characterize them according to immunological markers.
A cluster analysis was also performed in CVID patients.
PHID complication analyses
PHID complications were described in each subgroup of
patients identified by the cluster analysis in order to pro-
vide clinical-immunological links. These complications are
those defined by H Chapel et al. [6] to distinguish different
clinical phenotypes (autoimmunity, lymphoid hyperplasiaand chronic enteropathy) and granulomatous disease and
splenomegaly in addition [12]. Univariable logistic regres-
sion was performed to study the association between
PHID complications and the 23 immunological markers
(variables with a p-value < 0.25 were further tested). A
forward-selection procedure was used to build a final mul-
tivariable model. The first marker included in the model
was the most significant in univariable analysis. The next
variable included was the one with most significant associ-
ation with complications in the remaining set and so on
until any additional marker became non significant. As
the immunological markers in our study were expressed
in different units, we reported the Odds Ratio (OR) per 1
standard deviation for a unit free representation.
CVID substudy
The most consensual classification in symptomatic PHID
concerns CVID. EUROclass [5] is the classification com-
monly used in CVID, segregating patients with nearly absent
B cells (less than 1%), severely reduced switched memory B
cells (less than 2%), and expansion of CD21low B cells (more
than 10%). To evaluate if T-cell markers could improve this
classification [28], we evaluated the improvement in predict-
ive value for CVID complications by a net reclassification
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lities of CVID complications using two models: one with
EUROclass, the other with EUROclass and CD8+ HLA-
DR + (the most significantly associated in our analyses).
Based on these two models, we categorized the predicted
probabilities into two clinical meaningful categories
(probability < 50% or ≥ 50%) and cross-tabulated the clas-
sifications. The improvement in reclassification can be
quantified as the sum of differences in proportion of indi-
viduals moving up minus the proportion moving down for
people who developed complications and the proportion
of individuals moving down minus the proportion moving
up for people who didn’t develop complications. Predict-
ive capacity was also evaluated using the area on the re-
ceiving operating characteristics curve (c statistics).
Results
Patient characteristics
Sociodemographic and clinical characteristics
Between January 2007 and March 2010, 81 PHID patients
were enrolled in the ALTADIH Cohort (among whom 33
were also included in the DEFI Cohort), including 57 CVID




Median age at diagnosis in years (interquartile range)
Median age at enrolment in years (interquartile range)
Clinical data, n (%)
Respiratory tract infections













Chronic inflammatory intestinal disease
Therapeutic data, n (%)
Subcutaneous or intravenous immunoglobulin substitution
*Autoimmune anemia, autoimmune neutropenia, autoimmune thrombocytopenia,
†Location of biopsy proven granuloma: lymph node, digestive tract, spleen, bone nGood’s syndrome. At the time of evaluation, none of the
PHID patients had evidence of an acute infection. The ma-
jority of patients were followed at the Bordeaux University
Hospital (66 patients). Baseline epidemiological and clinical
characteristics are reported in Table 1. Of the 81 patients,
59% were women. The median age at PHID diagnosis was
41 years old (IQR: 35–54). The most frequent symptoms
in disease histories were respiratory tract infections.
Altogether, 38% of the patients developed one or more
complications: splenomegaly, autoimmune manifestations,
granulomatous disease, lymphoid hyperplasia and/or
chronic enteropathy (Table 1). More than 80% of the
patients were given subcutaneous or intravenous im-
munoglobulin substitution regimen.
Biological characteristics
Immunoglobulin serum levels before substitution for IgG,
IgA and IgM in PHID patients were significantly reduced:
baseline levels IgG (median: 4.3, IQR: 3.1–5.3 g/L; normal
range: 6.6–12.8 g/L), IgA (median: 0.5, IQR: 0.05–1.2 g/L;
normal range: 0.7–3.4 g/L), IgM (median: 0.4, IQR: 0.2–
0.8 g/L; normal range: 0.5–2.1 g/L). Specifically, in CVID



















Hashimoto thyroiditis, Goujerot-Sjögren syndrome.
arrow.
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median baseline IgM was 0.3 g/L (IQR: 0.1-0.6 g/L). Base-
line immunological marker values in PHID patients are
reported in Table 2 (values of normal patients are reported
in Additional file 4: Table S2). Some patients were included
in ALTADIH at diagnosis, before the introduction of IgG
replacement therapy, and had a longitudinal follow-up of
their immunological parameters. The replacement therapy
did not change the values of these parameters on two years
of monitoring.
Principal component analysis of differentiation, activation
and regulation markers of B and T-lymphocytes, natural
killer cells, dendritic cells and T-cells expressing a
gamma/delta TCR
For studying the association between the various im-
munological markers reported in the pathogenesis ofTable 2 Baseline immunological marker values of 81 PHID pa
Un
Total circulating lymphocytes (TCL) ce




Marginal zone CD27 + IgD+ %
Switched memory CD27 + IgD- %





Naïve CD45RA + CCR7+ %
Central memory CD45RA-CCR7+ %
Effector memory CD45RA-CCR7- %
Terminal effector CD45RA + CCR7- %
Immunosenescent CD8 + CD57+ %
Activated T cells
HLA-DR CD3 + HLA-DR+ %
CD4 + HLA-DR+ %
CD8 + HLA-DR+ %
Regulatory T cells CD4 + CD25 + CD127- ce





Gammadelta 2 cells %
IQR, interquartile range.PHID, statistical analyses would have been hampered by
the high number of markers studied, some of them be-
ing highly correlated (e.g. activation markers). In order
to circumvent these biases, we used PCA to reduce the
multidimensionality of the dataset and capture immuno-
logically relevant information. The first two principal
components accounted for 43% of the variability among
immunological markers (Figure 1). The first principal
component, accounting for 27% of the marker variabil-
ity, separated regulatory T-cells from activated cells
(HLA-DR + on CD3+, CD4+ and CD8+ grouped to-
gether) and CD19 + CD27 + IgD- switched memory B
cells from CD19 + CD27-IgD + naïve B cells. The second
principal component, which accounted for 16% of vari-
ability, mainly represented T-cell differentiation, oppo-
sing CD45RA+CCR7+ naïve CD8+ T cells and CD45RA+
CCR7- terminal effector CD8+ T cells. Activated CD3+,tients, ALTADIH Cohort 2007-2010
it Median IQR
lls/mm3 1384 (1017, 2000)
lls/mm3 128 (62, 193)
TCL 9.37 (6.21, 12.91)
CD19+ 74.01 (56.42, 83.35)
CD19+ 2.62 (1.86, 5.16)
CD19+ 9.42 (4.70, 15.37)
CD19+ 8.07 (3.63, 19.45)
lls/mm3 1078 (746, 1585)
lls/mm3 657 (422, 941)
lls/mm3 329 (228, 524)
1.99 (1.30, 2.70)
CD8+ 18.01 (6.79, 36.07)
CD8+ 1.25 (0.59, 2.48)
CD8+ 34.39 (24.47, 46.90)
CD8+ 33.48 (23.31, 48.26)
CD8+ 15.97 (8.04, 31.75)
CD3+ 12.87 (7.99, 20.37)
CD4+ 7.96 (5.14, 13.79)
CD8+ 24.49 (14.31, 41.11)
lls/mm3% TCL 32 1.10 (16, 63) (0.51, 1.76)
lls/mm3 126 (75, 194)
l 9381 (6597, 15611)
l 4671 (2810, 7427)
lls/mm3 33 (15, 72)
GD 56.32 (22.19, 77.17)
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positively correlated to each other in PCA (Spearman
rank correlation coefficient r = 0.88 between CD3+
HLA-DR + and CD4+ HLA-DR+; r = 0.90 between
CD3+ HLA-DR + and CD8+ HLA-DR+; r = 0.70 be-
tween CD4+ HLA-DR+ and CD8+ HLA-DR+). HLA-DR+
activation markers were also correlated to CD45RA+CCR7-
terminal effector CD8+ T cells and to CD8 +CD57+,
known to be a marker of senescence [30]. Hence, this
first analysis and an additional analysis extended to 38
markers available on 72 patients including CD21+ B
cells (see Additional file 5: Figure S3) led us to conclude
that all activation markers were highly correlated and
one of them could be chosen to reflect alone the T-cell
activation process. In addition, the first two components
defined an upper-left corner grouping HLA-DR + activa-
tion markers with CD45RA +CCR7- terminal effector
CD8+ T cells and the CD8 + CD57+ senescence marker.
PCA using 23 immunological markers of CVID pa-
tients only (excluding IgG SubClass Immuno deficient
and Good`s patients) gave consistent results as those ob-
served with the whole PHID population.
Classification of PHID patients according to cluster
analysis
Next, an unsupervised classification was performed to de-





Figure 2 Classification of 79 PHID patients by hierarchical cluster ana
2007-2010. The arrow defines the number of clusters. Patients with IgG sub
syndrome are depicted in blue. Other patients are CVID patients. The perceaccording to immunological markers. Hierarchical cluster
analysis could be performed for 79 PHID patients of the
81 in the ALTADIH cohort (2 CVID patients not classi-
fied). Based on cubic clustering criterion, we would have
chosen two clusters but the identification of five popula-
tions of PHID patients, as revealed by the five branches of
the tree down stream (Figure 2), was chosen as these five
clusters were clinically relevant. Clusters 1 and 2, made up
by patients with CVID or IgG subclass immunodeficiency,
were grouped together, separated from clusters 3, 4 and 5,
mainly made up by patients with CVID or either Good’s
syndrome. In the cluster analysis in CVID diagnoses
(excluding patients with Good’s syndrome and IgG sub-
class immunodeficiency), the patients were grouped in the
same way than in the previous cluster analysis performed
on the whole population (identification numbers of CVID
patients given for detailed parallel between Figure 2 and
Additional file 6: Figure S4).
The projection of PHID patients, classified in the
above 5 defined clusters, onto the plan spanned by the
first two principal components led to define their im-
munological characteristics (Figure 3 that needs to be
read in conjunction with Figure 1; Table 3). For example,
patients plotted in the upper-left corner of Figure 3,
mainly patients of cluster 4, are characterized by vari-
ables plotted in the same quadrant in Figure 1, in
particular HLA-DR +markers. Thus, the 33 patients




lysis, according to 23 immunological markers. ALTADIH Cohort,
class immunodeficiency are depicted in green. Patients with Good’s
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Figure 3 Immunological interpretation of 5 clusters of CVID plotted on the first two principal components. ALTADIH Cohort, 2007-2010.
The percentage of CVID complications, noted next to the clusters, increased in a clockwise manner as phenotypes approach the projection of
activated HLA-DR +markers plotted in Figure 1 (red arrow).
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tive immunity. They were represented on the upper-
right corner that grouped innate cells, CD19+ B-cells,
CD19 + CD27 + IgD- switched memory B-cells, CD3+,
CD4+, CD8+ T-cells, and regulatory T-cells (Figure 1).
Cluster 2 (lower-right corner, Figure 3) represented 18
patients (8 CVID patients and 10 IgG SD patients) char-
acterized by increased naïve CD8+ T-cells. Cluster 1 and
cluster 2 looked similar and were combined in an up
stream clustering. Cluster 3 (1 patient with Good’s syndrome
and 3 CVID patients) and cluster 4 (8 CVID patients) were
characterized by an increase of HLA-DR + activation, ter-
minal effector CD8+ T cells and immunosenescence
marker (Table 3). As expected, these patients were repre-
sented in the upper-left corner near CD3+, CD4+ and
CD8+ T cells expressing HLA-DR+, CD45RA +CCR7-
terminal effector CD8+ T cells, and the CD8 + CD57+
marker (Figure 1). In cluster 3, one CVID patient had
been splenectomized before enrolment (in 2001). In this
patient, splenectomy deeply affects the absolute numbers
but not grossly the percentages of the lymphocyte subpop-
ulations in the blood. In parallel, the patient with Good’ssyndrome in cluster 3 was differently plotted, i.e. in the
upper-right corner near CD8+, reflecting the high blood
CD8+ T-cell absolute numbers known in Good’s syn-
drome. Cluster 5 (lower-left corner, Figure 3) consisted
of 16 patients with B-cell deficiency (13 CVID, 1 IgG SD
and 2 Good’s syndrome): the lower-left corner where no
immunological parameters are plotted has to be inter-
preted as the symmetrical and diagonal opposite of the
upper-right corner. Thus, the meaning of cluster 5
(lower-left corner, Figure 3) is a cluster gathering B-cell
deficiencies because the patients are plotted on the op-
posite corner of the plot of CD19+, CD27 + IgD+,
CD27 + IgD-, CD27-IgD- which all are markers plotted
in the upper-right corner. Table 3 confirms the given
interpretation of the clusters.
PHID complications according to clusters and T-cell
activation
Interestingly, the proportion of patients with PHID compli-
cations (information not used in the previous analysis) var-
ied significantly between the clusters: 15%, 33%, 75%, 88%
and 63% in clusters 1 to 5 respectively (Figure 3, Table 4).
Table 3 Baseline immunological characteristics of 5 clusters of 79 PHID patients, ALTADIH Cohort, 2007-2010
Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5
n = 33 n = 18 n = 4 n = 8 n = 16
IgG g/L 4.37 (3.80, 5.32) 5.73 (4.7, 6.3) 4.68 (2.69, 5.29) 1.44 (0.30, 2.71) 3.69 (1.65, 4.22)
IgA g/L 0.63 (0.14, 1.62) 1.02 (0.07, 1.55) 0.60 (0.04, 2.09) 0.15 (0.01, 0.43) 0.19 (0.05, 0.79)
IgM g/L 0.55 (0.31, 1.09) 0.48 (0.24, 0.78) 0.54 (0.34, 0.62) 0.16 (0.05, 0.42) 0.27 (0.20, 0.47)
B cells
CD19+ cells/mm3 157 (128, 244) 128 (102, 211) 49 (20, 87) 122 (94, 176) 51 (29, 119)
CD27-IgD+ % CD19+ 68.85 (52.03, 74.47) 68.89 (57.94, 77.24) 49.52 (10.73, 80.43) 90.89 (82.94, 93.31) 84.03 (70.93, 90.82)
CD27-IgD- % CD19+ 2.80 (2.18, 4.38) 3.90 (2.24, 6.42) 6.13 (2.64, 23.40) 2.40 (1.67, 2.58) 2.65 (1.72, 4.22)
CD27 + IgD+ % CD19+ 15.01 (10.11, 23.19) 10.53 (4.42, 13.73) 5.67 (2.43, 8.57) 3.57 (2.21, 7.20) 4.92 (1.32, 7.92)
CD27 + IgD- % CD19+ 14.39 (7.08, 20.05) 13.93 (7.26, 24.33) 7.77 (2.43, 19.38) 2.55 (0.94, 3.91) 2.97 (0.36, 6.66)
T cells
CD3+ cells/mm3 1363 (1076, 1787) 1045 (883, 1456) 2756 (1472, 4183) 831 (658, 1075) 579 (407, 837)
CD4+ cells/mm3 835 (571, 1214) 789 (573, 967) 848 (609, 1227) 382 (302, 565) 308 (244, 565)
CD8+ cells/mm3 477 (358, 604) 270 (159, 383) 1621 (710, 2682) 293 (196, 362) 213 (141, 266)
CD4+/CD8+ ratio 1.89 (1.45, 2.42) 2.77 (2.31, 4.08) 0.60 (0.42, 1.06) 1.26 (0.67, 2.65) 1.89 (1.17, 2.61)
CD8+ T cells
CD45RA + CCR7+ % CD8+ 19.05 (11.11, 34.59) 28.47 (13.32, 43.67) 1.52 (0.56, 2.75) 4.91 (1.53, 53.19) 35.56 (10.29, 53.19)
CD45RA-CCR7+ % CD8+ 0.83 (0.46, 1.90) 4.60 (1.96, 7.97) 0.53 (0.21, 0.82) 0.82 (0.30, 1.20) 1.37 (0.85, 1.96)
CD45RA-CCR7- % CD8+ 31.28 (24.26, 36.96) 43.13 (32.60, 57.14) 36.82 (16.56, 57.25) 39.24 (30.69, 59.20) 29.14 (17.47, 42.55)
CD45RA + CCR7- % CD8+ 41.48 (32.61, 52.32) 22.30 (16.87, 27.10) 40.75 (13.96, 59.90) 48.28 (30.47, 63.41) 29.25 (18.76, 39.37)
CD8 + CD57+ % CD8+ 17.52 (9.42, 30.97) 7.38 (4.41, 15.97) 27.36 (19.36, 47.30) 39.61 (33.78, 51.16) 13.51 (8.35, 23.44)
Activated T cells
CD3 + HLA-DR+ % CD3+ 12.04 (7.62, 16.95) 9.87 (7.11, 12.83) 52.00 (32.71, 59.56) 46.56 (40.76, 57.25) 13.65 (6.19, 20.33)
CD4 + HLA-DR+ % CD4+ 5.88 (4.94, 9.17) 6.75 (4.95, 9.13) 48.30 (26.32, 56.25) 43.87 (30.88, 49.95) 11.54 (6.52, 18.33)
CD8 + HLA-DR+ % CD8+ 25.48 (14.86, 31.93) 19.73 (14.18, 26.44) 53.48 (37.05, 65.52) 62.14 (47.01, 76.39) 15.12 (10.65, 28.64)
Regulatory T cells cells/mm3 54 (33, 76) 41 (24, 82) 18 (13, 22) 19 (12, 24) 15 (8, 18)
NK cells cells/mm3 143 (100, 214) 174 (121, 230) 268 (146, 388) 75 (55, 103) 41 (26, 70)
Dendritic cells
Myeloid /ml 11940 (8751, 17805) 11422 (6616, 13457) 9122 (5662, 29989) 7795 (4086, 10548) 5420 (4107, 9683)
Plasmacytoid /ml 7217 (4801, 11084) 6152 (3599, 9836) 2771 (1766, 8490) 3073 (1351, 3618) 2766 (2194, 4255)
Gammadelta cells cells/mm3 44 (20, 74) 27 (11, 54) 396 (178, 579) 19 (6, 92) 16 (9, 26)
Gammadelta 2 % GD 62.96 (40.85, 73.68) 78.71 (75.00, 89.39) 13.40 (8.77, 30.62) 6.59 (4.09, 25.61) 25.00 (12.41, 55.96)
Results are expressed as medians (interquartile range values).
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http://www.biomedcentral.com/1471-2172/15/13As shown by the dendrogram (Figure 2), clusters 3, 4 and 5
were closer to each other than clusters 1 and 2, in which
the rate of complications was the lowest. Among the 8 pa-
tients in cluster 4, 7 (88%) presented with a splenomegaly
(14 splenomegaly recorded in the cohort) and 4 (50%) with
a granulomatous disease (9 granulomatous diseases re-
corded in the cohort). Patients in cluster 5, characterized by
a severe loss of switched memory B cells, also presented a
high percentage of complications (63%) (Figure 3, Table 4).
In Figure 3, the highest percentages of complications (from
clusters 3 and 4) are in the upper-left corner, and the lowest
(from cluster 1) on the upper-right. Hence, visually, compli-
cation rates increased in a clockwise manner.To quantify the independent effects of immunological
markers, we then performed a supervised analysis based
on a logistic regression model. As the activated HLA-
DR + CD3+, CD4+ and CD8+ T-cells were correlated
positively in the PCA, CD8+ HLA-DR + was chosen for
the ascendant multivariable analysis (as it was the most
significantly associated with PHID complications in uni-
variable analysis (Table 5). The final model contained
the following three markers. Increased CD8+ HLA-DR +
T-cells were strongly associated with PHID complications
(odds ratio per one standard deviation = 2.55; confidence
interval [1.33; 4.89]; p-value = 0.0047). Both decreased
plasmacytoid dendritic cells (odds ratio per one standard
Table 4 Type of PHID and PHID complications in 5 clusters of 79 PHID patients, ALTADIH Cohort, 2007-2010
Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5
n = 33 n = 18 n = 4 n = 8 n = 16
n % n % n % n % n %
Type of PHID
CVID 23 (70) 8 (44) 3 (75) 8 (100) 13 (82)
IgG subclass deficiency 10 (30) 10 (56) 0 (0) 0 (0) 1 (6)
Good’s syndrome 0 (0) 0 (0) 1 (25) 0 (0) 2 (12)
PHID complications (at least one of the following) 5 (15) 6 (33) 3 (75) 7 (88) 10 (63)
Lymphoid hyperplasia 2 (6) 5 (28) 1 (25) 3 (38) 5 (31)
Splenomegaly 1 (3) 2 (11) 1 (25) 7 (88) 3 (19)
Autoimmune manifestations 3 (9) 1 (5) 1 (25) 2 (25) 7 (44)
Granulomatous disease 0 (0) 1 (5) 2 (50) 4 (50) 2 (13)
Villous atrophy 0 (0) 2 (11) 0 (0) 0 (0) 3 (19)
Chronic inflammatory intestinal disease 0 (0) 2 (11) 1 (25) 1 (13) 0 (0)
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http://www.biomedcentral.com/1471-2172/15/13deviation = 0.49; confidence interval [0.25; 0.96]; p value =
0.0363) and decreased switched memory B cells (odds ra-
tio per one standard deviation = 0.51; confidence interval
[0.28; 0.94]; p value = 0.0312) were also associated with
PHID complications.
Classification of CVID patients according to EUROclass
and CD8+ HLA-DR +marker
In symptomatic PHID, the only disease for which a con-
sensual classification exists is CVID. Among the 57
CVID patients in the ALTADIH cohort, EUROclass dis-
tinguishes 1 patient with equal or less than 1% of B cells
of lymphocytes (B- group) from the 56 patients with a
higher percentage (B + group). B + patients were divided
into 15 patients with severe deficiency of class-switched
memory B cells (≤ 2% of B cells, smB- group) and 40 pa-
tients with more than 2% of class-switched memory B cells
(smB + group). The smB status of one patient could not be
evaluated. EUROclass also discriminates between patients
according to the expansion of CD21low B cells: above or
below 10% within B cells (CD21low versus CD21norm). In
our study, among 14 PHID patients with splenomegaly,
11 (79%) were classified in the CD21low group.
As we found a strong association between PHID compli-
cations and increased CD8+ HLA-DR +T-cells (expressed
as percentages of CD8+ lymphocytes) and because CD8+
HLA-DR + has been involved in CVID [12], we examined
whether the inclusion of CD8+ HLA-DR + in addition to
EUROclass criteria, would improve the prediction of CVID
complications (Table 6). Among 19 patients with CVID
complications and classified with less than 50% risk using
EUROclass, 10 were reclassified with a risk greater than
50% when adding the CD8+ HLA-DR + activation marker.
Moreover, the addition of CD8+ HLA-DR + to the model
increased its predictive value (c statistic 0.57 withoutCD8+ HLA-DR + versus 0.77 with CD8+ HLA-DR+, a
value close to 1 indicating a good prediction). Specifically,
adding CD8 +HLA-DR + to EUROclass model leads to a
substantial increase in sensitivity (from 24% to 60%) and
some loss of specificity (from 90% to 80%) (Additional file
7: Tables S3 and Additional file 8: Table S4).
Discussion
In the present study, we focused on three PHID in
adults with symptomatic implications: CVID, IgG SD
and Good’s syndrome (referred in the 2011 update of
Primary Immunodeficiency by the International Union
of Immunological Societies [1]). We used unsupervised
and supervised statistical methods on a cohort of 81
PHID patients in an attempt to select relevant markers
that may be useful for diagnosis and prognosis of these
patients.
Our rationale to pool patients diagnosed with CVID,
IgG SubClass Immuno deficient and Good`s patients,
and thus, to include in the ALTADIH cohort the active
file of PHID patients with symptoms in Aquitaine,
South-Western France, was based on the following argu-
ments: 1) Because of its complexity, distinguishing pa-
tients with symptomatic PHID can be challenging for
the diagnosis and the treatment. That is why we did not
focus only on CVID patients, and we wanted to address
the symptomatic PHID population seen in clinical rou-
tine practice by physicians, including IgG SubClass
Immuno deficient patients as well as Good's patients;
2) Literature on IgG subclass deficiency is poor and im-
munological characteristics of these patients have not
been explored as they have been in CVID. Indeed, IgG
subclass deficiency may progress to have typical CVID
[3]. Thus, the study of both CVID and IgG subclass defi-
ciency in a combined analysis was a novel aspect of our
Table 5 Immunological markers association with CVID complications
Unit Odds ratio 95% confidence interval p-value
B cells
CD19+ cells/mm3 0.65 [0.36; 1.15] 0.1373
CD27-IgD+ % CD19+ 1.49 [0.89; 2.48] 0.1310
CD27-IgD- % CD19+ 0.54 [0.24; 1.23] 0.1401
CD27 + IgD+ % CD19+ 0.62 [0.34; 1.12] 0.1124
CD27 + IgD- % CD19+ 0.93 [0.29; 0.86] 0.0119
T cells
CD3+ cells/mm3 0.68 [0.40; 1.17] 0,1646
CD4+ cells/mm3 0.45 [0.26; 0.78 ] 0,0046
CD8+ cells/mm3 1.04 [0.66; 1.62 ] 0.8818
CD4+/CD8+ ratio 0.99 [0.63; 1.56 ] 0.9649
CD8+ T cells
CD45RA + CCR7+ % CD8+ 0.69 [0.43; 1.13] 0.1385
CD45RA-CCR7+ % CD8+ 0.75 [0.46; 1.25] 0.2710
CD45RA-CCR7- % CD8+ 1.38 [0.86; 2.20] 0.1800
CD45RA + CCR7- % CD8+ 0.77 [0.48; 1.23] 0.2666
CD8 + CD57+ % CD8+ 1.30 [0.83; 2.06] 0.2567
Activated T cells
CD3 + HLA-DR+ % CD3+ 2.99 [1.56; 5.73] 0.0010
CD4 + HLA-DR+ % CD4+ 2.70 [1.40; 5.23] 0.0032
CD8 + HLA-DR+ % CD8+ 2.75 [1.54; 4.90] 0.0006
Regulatory T cells cells/mm3 0.41 [0.22; 0.78] 0.0065
Natural Killer cells cells/mm3 0.75 [0.46; 1.21] 0.2369
Dendritic cells
Myeloid /ml 0.65 [0.36; 1.17] 0.1532
Plasmacytoid /ml 0.37 [0.18; 0.73] 0.0046
Gammadelta cells cells/mm3 1.30 [0.79; 2.13] 0.3028
Gammadelta 2 cells % GD 0.52 [0.32; 0.85] 0.0087
Univariable logistic regression analysis (Odds ratio per 1 standard deviation).
ALTADIH Cohort, 2007-2010.
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ciency) was listed as a predominantly antibody deficiency
in the 2009 update of Primary Immunodeficiency by the
International Union of Immunological Societies [1].
Based on our view to include eligible patients with
symptomatic PHID seen in routine clinical practice and
this pivotal article, we do not have any arguments to ex-
clude it from eligibility criteria.
First, PCA gave some insight to the association be-
tween the 23 immunological markers measured. An in-
crease in the proportion of HLA-DR + T-cell as an
indication for activation, positively correlated to an in-
crease in CD45RA + CCR7- terminal effector CD8+ T-
cells and to the CD8 + CD57+ immunosenescence
marker, defined one group of markers. In parallel, a de-
fect in B-cell differentiation (increased CD19 + CD27-IgD + naïve B cells and by symmetry, decreased CD19 +
CD27 + IgD- switched memory B cells) might identify
another distinct pathway. The PCA gave the opportunity
to explore and to observe graphically the links between
immunological markers and we made the choice to
present the plane spanned by the two first principal
components because they explained the most the data
variability (43%). Next, we performed a hierarchical clus-
ter analysis on the basis of the cell profile under investi-
gation. As it was more relevant biologically, cluster
analysis was performed with immunological markers ra-
ther than with principal components. Thus, the variance
left on other principal components was not an obstacle
for the cluster analysis.
The cluster analysis separated five major groups in our
PHID population with distinct rates of complications.
Table 6 Reclassification of 55 CVID patients smB+/-, separated according to experience of complications
Model with EUROclass Model with EUROclass and CD8+ HLA-DR+ Total
Predicted probabilities (%) < 50% ≥ 50%
Patients who experienced CVID complications
< 50% 9 19
≥ 50% 1 5 6
Total 10 15 25
Patients who didn’t experience CVID complications
< 50% 22 5 27
≥ 50% 2 1 3
Total 24 6 30
ALTADIH Cohort, 2007-2010.
The agreements between the two models for classifying the patients are depicted in gray. Adding CD8 + HLA-DR + to EUROclass model leads to better determine
CVID complications for 10 patients who experienced CVID complications (upward movement in category for patients who experienced CVID complications) and to
better determine the absence of CVID complications for 2 patients who did not experience CVID complications (downward movement in category for patients
who did not experience CVID complications). In parallel, it leads to worsened classification for 1 patient who experienced CVID complications (downward
movement in category for patients who did experience CVID complications) and 5 patients who did not experience CVID complications (upward movement in
category for patients who did not experience CVID complications).
The positive net reclassification improvement (0.26) revealed that CD8+ HLA-DR + offers improved prediction of CVID complications.
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IgG SD and 2 with Good’s syndrome), 63% of whom
suffering PHID complications, were characterized by a
severe loss of CD19 + CD27 + IgD- switched memory
B-cells whereas patients in clusters 3 and 4, mainly with
CVID (75% and 88% of whom having PHID complica-
tions, respectively) were characterized by increased
HLA-DR + activation of T-cells. Regarding available data
for activated T cells or B cell subsets for 12 normal
healthy donors (Additional file 4: Table S2) and data
from PHID patients in Table 3, activated T cells were
higher in PHID patients from clusters 3 and 4, and
switched memory B cells were particularly lower in
PHID patients from clusters 4 and 5. Furthermore, the
strong association we found between PHID complica-
tions and increased CD8+ HLA-DR + T-cells reinforced
the importance of the link between T-cell activation and
clinical complications. More importantly, in a substudy
with CVID patients, the classification that added CD8+
HLA-DR + to EUROclass was superior to the EUROclass
model in predicting CVID complications. The advantage
of adding CD8+ HLA-DR + to EUROclass resulted in a
substantial increase of sensitivity and some loss of speci-
ficity to determine CVID complications. As a consensus
does not exist for the cut-off of probability, we explored
a threshold of 50% (Additional file 7: Tables S3,
Additional file 8: Table S4).
Our results on switched memory B-cell defect, defin-
ing PHID cluster 5 in particular, are consistent with pre-
vious findings on B-cell phenotype in PHID [4,5,9,10].
Our study also highlights the importance of considering
T-cell activation [12,13] in PHID (clusters 3 and 4 with
increased T-cell activation with the highest percentage
of complications, comprising mainly CVID patients andthe three patients with Good’s syndrome identified in
our cohort as PHID types). Moreover, the occurrence of
two complications considered in addition to those de-
fined by H Chapel et al. [6] (ie: splenomegaly and granu-
lomatous disease) were found with the highest frequency
in the clusters 3 and 4 with increased T-cell activation,
suggesting that the HLA-DR + activation marker could
help to discriminate them. However, this cross-sectional
analysis of data from the ALTADIH cohort does not
allow us to determine whether increased T-cell activa-
tion is a causal factor of PHID progression or if it is in-
duced by PHID complication. Only longitudinal analyses
of activation markers would help in deciphering the role
of T-cell activation, determining whether or not patients
with normal phenotype will progress to an abnormal
phenotype and will develop complications. Adding T-cell
parameters for discriminating PHID patients is import-
ant to better dissect these heterogeneous syndromes.
This has been previously suggested in CVID [31] by sev-
eral authors especially the Rome group [11] (Giovannetti
et al.) as well as the Czech group [32] (Vlková et al.) and
the French DEFI group [7] (Mouillot et al.). These au-
thors suggested CD4 naïve T cell percentage as add-
itional marker in CVID. Markers of CD4+ T-cell
differentiation were not performed in our study. At the
time of research protocol writing, set up in 2005, the im-
portance of CD4+ T-cell differentiation has not been re-
ported in PHID literature as it would be few years later.
Thus, markers of CD4+ T-cell differentiation have not
been planned in the ALTADIH protocol and the pro-
spective design of the study did not allow for this B-cell
marker to be assessed afterwards. This is a clear limita-
tion of the study. However, previous authors also
highlighted that a decrease of naive CD4 cells was also
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http://www.biomedcentral.com/1471-2172/15/13associated to T-cell activation and it would not be un-
reasonable to consider T-cell activation as an indirect
marker of decreased naive CD4 cells in our study. In
addition, the signification of the memory status in the
CD4+ compartment has been a subject of debates until
recently as exemplified by Su LF, et al. [33].
Conclusion
To date, PHID diseases have only been examined through
the analysis of separated compartments of the immune
system. On this ground, our approach of combining a
wide set of immunological markers using appropriate stat-
istical methods for the high-dimensional is a novel aspect
in PHID. The meaning of the identified clusters would
need to be validated with a larger number of patients, for
example the French national prospective Cohort DEFI [7].
It would be the opportunity to include markers of CD4+
T-cell differentiation in the analyses and consider potential
other markers, as mucosal associated invariant T cells
[34,35], recently reported in CVID [36].
In conclusion, by combining a wide set of immuno-
logical markers, this study reveals that T-cell activation
could be of additional value to discriminate patients with
specific PHID features. Such information might have im-
plications for diagnosis and clinical management. A sys-
tematic recording of the HLA-DR + phenotype in every
patient with PHID seems relevant.
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